These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38964502)

  • 1. Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay.
    Liu M; Vathiotis I; Robbins CJ; Chan NNN; Moutafi M; Burela S; Xirou V; Schalper KA; Herbst RS; Syrigos K; Rimm DL
    Mod Pathol; 2024 Sep; 37(9):100556. PubMed ID: 38964502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.
    Shiraishi A; Oh-Hara T; Takahashi Y; Uchibori K; Nishio M; Katayama R
    Biochem Biophys Res Commun; 2024 Sep; 725():150255. PubMed ID: 38897043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: a case report.
    Güren AK; Kocaaslan E; Ağyol Y; Majidova N; Sever N; Erel P; Çelebi A; Arikan R; Işik S; Sari M; Bayoğlu İV; Köstek O
    Anticancer Drugs; 2024 Sep; 35(8):769-773. PubMed ID: 39115060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
    Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
    J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
    Indini A; Rijavec E; Grossi F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab Deruxtecan in
    Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
    N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable responses to trastuzumab deruxtecan in patients with leptomeningeal metastases from breast cancer with variable HER2 expression.
    Rogawski D; Cao T; Ma Q; Roy-O'Reilly M; Yao L; Xu N; Nagpal S
    J Neurooncol; 2024 Oct; 170(1):209-217. PubMed ID: 39073687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer: a plain language summary of the DESTINY-Lung01 study.
    Smit EF
    Future Oncol; 2024; 20(27):1961-1971. PubMed ID: 39012221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
    Smit EF; Felip E; Uprety D; Nagasaka M; Nakagawa K; Paz-Ares Rodríguez L; Pacheco JM; Li BT; Planchard D; Baik C; Goto Y; Murakami H; Saltos A; Pereira K; Taguchi A; Cheng Y; Yan Q; Feng W; Tsuchihashi Z; Jänne PA
    Lancet Oncol; 2024 Apr; 25(4):439-454. PubMed ID: 38547891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.
    Moutafi M; Robbins CJ; Yaghoobi V; Fernandez AI; Martinez-Morilla S; Xirou V; Bai Y; Song Y; Gaule P; Krueger J; Bloom K; Hill S; Liebler DC; Fulton R; Rimm DL
    Lab Invest; 2022 Oct; 102(10):1101-1108. PubMed ID: 35595825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic
    Yun KM; Bazhenova L
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody-drug conjugate-resistant HER2-overexpressing breast cancer.
    Lee J; Kida K; Koh J; Liu H; Manyam GC; Gi YJ; Rampa DR; Multani AS; Wang J; Jayachandran G; Lee DW; Reuben JM; Sahin A; Huo L; Tripathy D; Im SA; Ueno NT
    J Exp Clin Cancer Res; 2024 Aug; 43(1):236. PubMed ID: 39164784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan in breast cancer.
    Martín M; Pandiella A; Vargas-Castrillón E; Díaz-Rodríguez E; Iglesias-Hernangómez T; Martínez Cano C; Fernández-Cuesta I; Winkow E; Perelló MF
    Crit Rev Oncol Hematol; 2024 Jun; 198():104355. PubMed ID: 38621469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CNS activity of trastuzumab deruxtecan in HER2-expressing non-small-cell lung cancer.
    Lazaratos AM; Petrecca K; Guiot MC; Jerzak KJ; Dankner M
    Lancet Oncol; 2024 Jul; 25(7):e282. PubMed ID: 38936381
    [No Abstract]   [Full Text] [Related]  

  • 15. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report.
    He X; Hou L; Bai J; Sun C; Wang D; An G
    Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.
    Garrido C; Manoogian M; Ghambire D; Lucas S; Karnoub M; Olson MT; Hicks DG; Tozbikian G; Prat A; Ueno NT; Modi S; Feng W; Pugh J; Hsu C; Tsurutani J; Cameron D; Harbeck N; Fang Q; Khambata-Ford S; Liu X; Inge LJ; Vitazka P
    Virchows Arch; 2024 Jun; 484(6):1005-1014. PubMed ID: 37857998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
    Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J
    Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.
    Cancer Discov; 2022 Oct; 12(10):2224. PubMed ID: 35984233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
    Lee J; Park YH
    Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody-drug conjugate.
    Edoardo C; Giuseppe C
    Expert Opin Investig Drugs; 2024 Aug; 33(8):851-865. PubMed ID: 38967422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.